Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Gets a Hold from HSBC

HSBC maintained a Hold rating on Shanghai Fosun Pharmaceutical (Group) Co with a HK$18.30 price target in a July 10 report, while shares closed at HK$16.34. Conversely, TipRanks data shows an analyst consensus of Moderate Buy for the company, with a higher consensus price target of HK$25.24.

In a report released on July 10, from HSBC maintained a Hold rating on Shanghai Fosun Pharmaceutical (Group) Co, with a price target of HK$18.30. The company’s shares closed last Tuesday at HK$16.34.

TipRanks Welcomes a New ETF – NYSE:RANK

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Shanghai Fosun Pharmaceutical (Group) Co has an analyst consensus of Moderate Buy, with a price target consensus of HK$25.24.